CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0146 (clinicaltrials.gov NCT No: NCT00304083)
Title:Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type I Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors
Principal Investigator:Joseph A. Ludwig
Treatment Agent:Dexrazoxane; Doxorubicin; Etoposide; Filgrastim; Ifosfamide; Mesna; Pegfilgrastim; Radiation; Surgical Procedure
Study Status:Terminated
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Sarcoma
Phase of Study:Phase II
Treatment Agents:Dexrazoxane
Doxorubicin
Etoposide
Filgrastim
Ifosfamide
Mesna
Pegfilgrastim
Radiation
Surgical Procedure
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:It is possible some patients will be admitted for surgery as part of the
treatment regimen to achieve local control of the disease. The length of stay
would be dependent on the surgical site - on average 5 -7 days.
Supported By:Department of Defense
Dept. of Defense
Return Visit:5 days consecutively for chemo treatment every 21 days . One to two times a
week for blood counts after the week of chemo.
Home Care:Neulasta sub-q injections.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Joseph A. Ludwig
Dept:Sarcoma Medical Oncology
For Clinical Trial Enrollment:713-792-3626
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults